<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03796442</url>
  </required_header>
  <id_info>
    <org_study_id>D-1812-024-991</org_study_id>
    <nct_id>NCT03796442</nct_id>
  </id_info>
  <brief_title>Comparison of Two Pericardial Bioprostheses in AVR</brief_title>
  <official_title>Early and 1-year Hemodynamic Performance and Clinical Outcomes After Aortic Valve Replacement Using Two Pericardial Bioprostheses: A Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare early and 1-year hemodynamic performance and clinical
      outcomes after aortic valve replacement using two pericardial bioprosthesis, Avalus and
      Carpentier Edwards Perimount Magna Ease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial was designed as a multicenter randomized, controlled trial to recruit 386 patients
      who undergo aortic valve replacement with pericardial bioprosthesis. Patients were randomized
      by use of a randomization table. Bioprosthesis was chosen between Avalus or Carpentier
      Edwards Perimount Magna Ease according to the randomization result. The primary end point is
      postoperative 1-year transvalvular mean pressure gradient. The secondary end points are
      postoperative 1-year effective orifice area, operative mortality, operative morbidities,
      1-year overall survival, 1-year freedom from cardiac death and 1-year freedom from
      valve-related events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>transvalvular mean Pressure Gradient (mPG)</measure>
    <time_frame>at postoperative 1 year</time_frame>
    <description>transvalvular mean pressure gradient measured by trans-thoracic echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effective orifice area (EOA)</measure>
    <time_frame>at postoperative 1 year</time_frame>
    <description>effective orifice area measured by trans-thoracic echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Op mortality</measure>
    <time_frame>at postoperative 30 days or at the time of discharge</time_frame>
    <description>any death within 30 days after surgery or during the same hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Op morbidities</measure>
    <time_frame>at postoperative 1 year</time_frame>
    <description>low cardiac output syndrome, bleeding reoperation, perioperative myocardial infarction, stroke, acute kidney injury, respiratory complication, new onset atrial fibrillation, mediastinitis, surgical wound infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>at postoperative 1 year</time_frame>
    <description>all deaths from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>at postoperative 1 year</time_frame>
    <description>Any death related to cardiac events, including sudden death during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic valve-related events</measure>
    <time_frame>at postoperative 1 year</time_frame>
    <description>valve-related mortality, thromboembolism, bleeding, endocarditis, reoperation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>AVALUS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who will undergo aortic valve replacement with Avalus bioprosthesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CEPME group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who will undergo aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVR with AVALUS</intervention_name>
    <description>aortic valve replacement with AVALUS bioprosthesis</description>
    <arm_group_label>AVALUS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVR with CEPME</intervention_name>
    <description>aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis</description>
    <arm_group_label>CEPME group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who are going to undergo aortic valve replacement with bioprosthesis

        Exclusion Criteria:

          -  heart failure with severe LV dysfunction (LV EF &lt;30%)

          -  active infective endocarditis

          -  with other critical cardiovascular disease (e.g. acute aortic dissection)

          -  with other critical comorbities by which the expected life span is less than 1 year

          -  inadequate participant by the researcher's discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Young Hwang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ho Young Hwang, MD, PhD</last_name>
    <phone>82-2-2072-3020</phone>
    <email>scalpel@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suk Ho Sohn, MD</last_name>
    <phone>82-2-2072-3897</phone>
    <email>xsshssx@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheong Lim, MD, PhD</last_name>
      <phone>82-31-787-7139</phone>
      <email>mluemoon@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Young Hwang, MD, PhD</last_name>
      <phone>82-2-2072-3020</phone>
      <email>scalpel@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Suk Ho Sohn, MD</last_name>
      <phone>82-2-2072-3897</phone>
      <email>xsshssx@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 1, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Ho Young Hwang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>aortic valve replacement</keyword>
  <keyword>bioprosthesis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared because it is not allowed by our institutional IRB.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

